| Dr Clayton Hoyt Isenberg, | |
|
1122 Tahoe Dr, Maumelle, AR 72113-5009 | |
| (501) 847-2880 | |
| (501) 847-2881 |
| Full Name | Dr Clayton Hoyt Isenberg |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1122 Tahoe Dr, Maumelle, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174122253 | NPI | - | NPPES |
| 196323407 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PD14513 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Clayton Hoyt Isenberg, 3801 Highway 5 N, Bryant, AR 72022-9028 Ph: (501) 847-2880 | Dr Clayton Hoyt Isenberg, 1122 Tahoe Dr, Maumelle, AR 72113-5009 Ph: (501) 847-2880 |
News Archive
RESILIENT was a single arm, open label, phase II/III study to test if label agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefit for patients with relapsed refractory metastatic malignancies.
FDA is releasing a redacted copy of a warning letter sent on October 15, 2010 to Mr. Austin J. DeCoster, owner of Quality Egg LLC of Galt, Iowa. Quality Egg LLC is one of two companies that recalled eggs in August 2010. Quality Egg LLC has not shipped eggs to the table market since the August recalls.
Incarcerated patients with chronic hepatitis C virus (HCV) infection are just as likely to respond to treatment for the disease as patients in the community, according to findings published in the October issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases.
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
Researchers at the Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, USA, showed that the SARS-CoV-2 spike E484K mutation reduces antibody neutralization.
› Verified 1 days ago
Mrs. Christen Erin Dalby, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 115 Commons Dr, Maumelle, AR 72113 Phone: 501-803-3274 | |
Dr. Brandon Achor, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1900 Club Manor Dr Ste 101a, Maumelle, AR 72113 Phone: 501-274-1130 Fax: 501-274-1131 | |
Justin Kerr, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 110 Commons Dr, Maumelle, AR 72113 Phone: 501-210-7670 | |
Dr. Amanda Kay Galiano, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8 Chicot Cv, Maumelle, AR 72113 Phone: 501-227-6115 | |
Leslyn Dyan Boyland, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 115 Commons Dr, Maumelle, AR 72113 Phone: 501-803-3274 | |
Bobby Tai Le, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 115 Commons Dr, Maumelle, AR 72113 Phone: 501-803-3274 |